A717 mAb

About Glycadia Pharmaceuticals

Glycadia Pharmaceuticals is targeting a critical unmet need in diabetes care by developing first-in-class therapies that directly address the root cause of diabetic complications: excess glycation of proteins. The company's lead asset, GLY-230, has completed Phase 1 trials and is being prepared for Phase 2 studies in diabetic nephropathy, positioning it as a potential disease-modifying agent. With a pipeline that includes both small molecules and monoclonal antibodies for microvascular and macrovascular diseases, Glycadia is operating in a massive market with over 100 million affected individuals in the US alone, where current standard of care fails to adequately control complications for the majority of patients.

Therapeutic Areas